5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional Flow ReserveDepartment of Cardiology, Skåne University Hospital, Clinical Sciences, Lund University, Lund, Sweden.
Department of Cardiology, University Hospital, University of Iceland, Reykjavik, Iceland.
Department of Cardiology, Skåne University Hospital, Clinical Sciences, Lund University, Lund, Sweden.
Department of Cardiology and Radiology, Helsingborg County Hospital, Helsingborg, Sweden.
Department of Cardiology, Karlstad Central Hospital, Karlstad, Sweden.
Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
Department of Cardiology and Radiology, Helsingborg County Hospital, Helsingborg, Sweden.
Department of Cardiology, Karlstad Central Hospital, Karlstad, Sweden.
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Cardiology, St Göran Hospital, Stockholm, Sweden.
Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
Department of Medical Sciences, Linköping University Hospital, Linköping, Sweden.
Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Department of Cardiology, Västmanland Hospital, Västerås, Sweden.
Department of Cardiology, Kalmar Hospital, Kalmar, Sweden.
Department of Cardiology, St Göran Hospital, Karolinska Institute, Stockholm, Sweden.
Department of Cardiology, Halmstad Hospital, Halmstad, Sweden.
Department of Cardiology, Skåne University Hospital, Clinical Sciences, Lund University, Lund, Sweden.
Show others and affiliations
2022 (English)In: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 79, no 10, p. 965-974Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Instantaneous wave-free ratio (iFR) is a coronary physiology index used to assess the severity of coronary artery stenosis to guide revascularization. iFR has previously demonstrated noninferior short-term outcome compared to fractional flow reserve (FFR), but data on longer-term outcome have been lacking.
OBJECTIVES: The purpose of this study was to investigate the prespecified 5-year follow-up of the primary composite outcome of all-cause mortality, myocardial infarction, and unplanned revascularization of the iFR-SWEDEHEART trial comparing iFR vs FFR in patients with chronic and acute coronary syndromes.
METHODS: iFR-SWEDEHEART was a multicenter, controlled, open-label, registry-based randomized clinical trial using the Swedish Coronary Angiography and Angioplasty Registry for enrollment. A total of 2,037 patients were randomized to undergo revascularization guided by iFR or FFR.
RESULTS: No patients were lost to follow-up. At 5 years, the rate of the primary composite endpoint was 21.5% in the iFR group and 19.9% in the FFR group (HR: 1.09; 95% CI: 0.90-1.33). The rates of all-cause death (9.4% vs 7.9%; HR: 1.20; 95% CI: 0.89-1.62), nonfatal myocardial infarction (5.7% vs 5.8%; HR: 1.00; 95% CI: 0.70-1.44), and unplanned revascularization (11.6% vs 11.3%; HR: 1.02; 95% CI: 0.79-1.32) were also not different between the 2 groups. The outcomes were consistent across prespecified subgroups.
CONCLUSIONS: In patients with chronic or acute coronary syndromes, an iFR-guided revascularization strategy was associated with no difference in the 5-year composite outcome of death, myocardial infarction, and unplanned revascularization compared with an FFR-guided revascularization strategy. (Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome [iFR SWEDEHEART]; NCT02166736)
Place, publisher, year, edition, pages
Elsevier, 2022. Vol. 79, no 10, p. 965-974
Keywords [en]
coronary physiology, fractional flow reserve, instantaneous wave-free ratio, percutaneous coronary intervention
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-98290DOI: 10.1016/j.jacc.2021.12.030ISI: 000766654300005PubMedID: 35272801Scopus ID: 2-s2.0-85125465946OAI: oai:DiVA.org:oru-98290DiVA, id: diva2:1647579
Funder
Novo NordiskAstraZeneca
Note
Funding agencies:
Philips Volcano
Medtronic
Boston Scientific and Philips Volcano
Boston Scientific
Abbott Laboratories
Sanofi-Pasteur
Volcano
2022-03-282022-03-282025-02-10Bibliographically approved